PoA = directional probability band (not FDA guidance).
Rule: FDA decision events get a %; data/webinars/conferences get N/A.
THE FRAME (MAR 9–15): “CMC PRINTS CLEAN → THREE STORYTAPE EVENTS → ONE VOLATILITY STACK (MDA)”
Last week’s clean CMC clock has now printed, and this week is mostly narrative-price discovery:
$LNTH ( ▲ 7.32% ) : PYLARIFY TruVu approved Fri Mar 6 → now a supply/capacity story, not a clock.
Mon 9:00am ET: NovaBridge (Nasdaq: NBP) VIS-101 Phase 2a call (retina “durability or bust”).
Tue 12:00pm ET: $GALT ( ▲ 6.45% ) belapectin NAVIGATE KOL (subgroup/biomarker “narrative repair”).
Wed (MDA): $BIIB ( ▼ 0.11% ) data + back-to-back late-breakers ($BBIO 2:00pm then $CAPR 2:45pm) = compressed neuromuscular volatility window.
WHAT PRINTED SINCE LAST MONDAY
LNTH — $LNTH ( ▲ 7.32% ) | PYLARIFY TruVu (new formulation) | FDA APPROVAL (Fri Mar 6) | PoA: N/A (resolved)
This printed as the clean CMC outcome: the new formulation supports higher radioactive concentration and about 50% larger batch production, with a 4Q26 phased launch aligned to Oct. 1 reimbursement codes.
Trade shifts to: execution + margin/supply narrative, not regulatory risk.
THIS WEEK’S HARD EVENTS (IN ORDER)
NBP — NovaBridge (Nasdaq: NBP) | VIS-101 (wet AMD) | Phase 2a data call: Mon Mar 9, 9:00am ET | PoA: N/A
This is a durability/differentiation tape versus Eylea/Vabysmo expectations.
Watch: effect size and any implied dosing-interval flexibility, safety tone, and how crisp the next-trial shape is.
This is a design + subgroup posture event, not a new-topline binary.
Watch: whether KOLs treat subgroup/biomarker signals as actionable and whether the next pivotal concept is framed cleanly around population + endpoint.
MDA WEEK (MAR 8–11): THE COMPRESSED WINDOW
BIIB — $BIIB ( ▼ 0.11% ) | high-dose nusinersen (SMA) | MDA data: Wed Mar 11 | PoA: N/A
This is an incumbent-optimization tape: confirmatory safety/durability framing rather than binary development risk. Biogen has said it will present new SMA data from DEVOTE/ONWARD at MDA.
BBIO — $BBIO ( ▼ 0.81% ) | BBP-418 (LGMD2I/R9) | Late-breaking oral: Wed Mar 11, 2:00pm ET | PoA: N/A
Interim FORTIFY update — the market will trade interpretability, not just biomarker movement.
Watch: ribitol/FKRP coherence and whether they bridge biomarker to functional meaning cleanly.
CAPR — $CAPR ( ▲ 6.63% ) | deramiocel (DMD) | Late-breaking oral: Wed Mar 11, 2:45pm ET | PoA: N/A
Key context remains: the company says the HOPE-3 CSR has been submitted to FDA in support of the ongoing BLA review.
Watch: PUL/functional effect size, cohort clarity, durability, and how cleanly the cardiac angle ties to meaningful function.
FORWARD CALENDAR (NEXT KNOWN HARD CLOCKS)
ALDX — $ALDX ( ▲ 4.58% ) | reproxalap (dry eye) | PDUFA: Mon Mar 16 | PoA: 65%
CRL-overhang name; the trade is labeling/efficacy posture. The March 16, 2026 PDUFA date remains the current target after the FDA extension tied to an added clinical study report/major amendment.
RLAY — $RLAY ( ▲ 1.11% ) | zovegalisib | ESMO TAT: Mon Mar 16 | PoA: N/A
Focus is data at the Phase 3 dose framing; Relay has said the presentation will include 400 mg BID fed, the Phase 3 dose. Watch whether tolerability stays clean versus PI3K baggage.
WEEKLY CALENDAR (ONE SCREEN)
Date | Ticker | Catalyst | PoA |
|---|---|---|---|
Mon Mar 9 (9:00am ET) | NBP | VIS-101 Phase 2a data call | N/A |
Tue Mar 10 (12:00pm ET) | $GALT | belapectin NAVIGATE KOL | N/A |
Wed Mar 11 | $BIIB | MDA data | N/A |
Wed Mar 11 (2:00pm ET) | $BBIO | MDA late-breaker | N/A |
Wed Mar 11 (2:45pm ET) | $CAPR | MDA late-breaker | N/A |
Mon Mar 16 | $ALDX | PDUFA | 65% |
Mon Mar 16 | $RLAY | ESMO TAT | N/A |
WEEKLY POSTURE (ONE PARAGRAPH)
This is a storytape week: LNTH’s clean CMC approval removes the only hard regulatory clock from last week, and the tape now trades on durability, interpretability, and next-trial clarity - first in retina (NBP), then liver (GALT), then a compressed neuromuscular volatility window at MDA (BIIB + BBIO → CAPR).
Tools we use: Market Chameleon (options/IV + unusual activity). We may earn a commission at no extra cost to you.
Disclaimer: informational only; not investment advice; biotech carries risk of total loss